{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:57:32Z","timestamp":1781636252697,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ameloblastoma is the most common odontogenic neoplasm of the jaws, characterized by locally aggressive behavior and high recurrence potential. Although its clinicopathologic features have been described in global populations, large-scale institutional data from the United States (U.S.) remain limited. This study aims to characterize the epidemiologic and clinicopathologic features of conventional ameloblastoma over a 22-year period and to identify factors associated with recurrence in cases submitted to a single U.S. academic surgical oral pathology laboratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review was conducted of 123 cases of conventional ameloblastoma submitted to the Surgical Oral Pathology Laboratory at the University of Iowa which receives specimens from various states in the U.S. Data included patient demographics, tumor site, radiographic findings, histologic subtypes, treatment modality, and follow-up information. Recurrence-free survival was analyzed using Kaplan-Meier and log-rank tests, and predictors of recurrence were evaluated by Cox proportional hazards modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 123 cases, the mean age was 51 years (range: 11-93), and 56.9% were male. Most tumors involved the mandible (91.9%). Of the 90 cases with available radiographic findings, 54.4% were unilocular, 37.8% multilocular, and 7.8% mixed radiolucent\u2013radiopaque. The most common histologic subtype was follicular admixed with other subtypes (61.8%). Among 39 patients with treatment data, 23 (59.0%) underwent resection, 11 (28.2%) had enucleation and curettage, and 5 (12.8%) received enucleation with peripheral ostectomy. Follow-up information was available for 35 patients, of whom 15 (42.9%) experienced recurrence within 8-360 months. Recurrence-free survival differed significantly by treatment modality (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.006), with resection associated with markedly improved outcomes compared with more conservative treatments (adjusted\n                      <jats:italic>p<\/jats:italic>\n                      = 0.028).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study reinforces the importance of surgical treatment selection in the prognosis of conventional ameloblastoma and highlights the need for careful surgical planning to minimize recurrence. Additionally, mixed histopathologic subtypes within the tumor limited the prognostic value of histologic subclassification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12105-026-01893-4","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:15:36Z","timestamp":1771920936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology and Clinicopathologic Features with Prognostic Implications of Conventional Ameloblastoma: A 22-Year Retrospective Study"],"prefix":"10.1007","volume":"20","author":[{"given":"Kittiphoj","family":"Tikkhanarak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Handoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hellstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Petrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erliang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Dunnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeez","family":"Butali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"1893_CR1","unstructured":"WHO Classification of Tumours Editorial Board (2023) Head and neck tumours. 5th ed. WHO classification of tumours series. International Agency for Research on Cancer, Lyon (France)"},{"key":"1893_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/odi.12646","volume":"24","author":"OA Effiom","year":"2018","unstructured":"Effiom OA, Ogundana OM, Akinshipo AO, Akintoye SO (2018) Ameloblastoma: current etiopathological concepts and management. Oral Dis 24:307\u2013316. https:\/\/doi.org\/10.1111\/odi.12646","journal-title":"Oral Dis"},{"key":"1893_CR3","doi-asserted-by":"publisher","unstructured":"Pogrel MA, Montes DM (2009) Is there a role for enucleation in the management of ameloblastoma? Int J Oral Maxillofac Surg 38. https:\/\/doi.org\/10.1016\/j.ijom.2009.02.018. :807\u2009\u2013\u200912","DOI":"10.1016\/j.ijom.2009.02.018"},{"key":"1893_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.oooo.2012.01.011","volume":"113","author":"K Dhanuthai","year":"2012","unstructured":"Dhanuthai K, Chantarangsu S, Rojanawatsirivej S, Phattarataratip E, Darling M, Jackson-Boeters L, Said-Al-Naief N, Shin HI, An CH, Hong NT, An PH, Thosaporn W, Lam-ubol A, Subarnbhesaj A (2012) Ameloblastoma: a multicentric study. Oral Surg Oral Med Oral Pathol Oral Radiol 113:782\u2013788. https:\/\/doi.org\/10.1016\/j.oooo.2012.01.011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1893_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/odi.13031","volume":"26","author":"FN Hendra","year":"2020","unstructured":"Hendra FN, Van Cann EM, Helder MN, Ruslin M, de Visscher JG, Forouzanfar T, de Vet HCW (2020) Global incidence and profile of ameloblastoma: a systematic review and meta-analysis. Oral Dis 26:12\u201321. https:\/\/doi.org\/10.1111\/odi.13031","journal-title":"Oral Dis"},{"key":"1893_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s41548-019-00018-6","volume":"3","author":"OO Soyele","year":"2019","unstructured":"Soyele OO, Akinshipo AO, Effiom OA, Omitola OG, Okoh D, Sigbeku O, Butali A, Adeola HA (2019) A multi-centre evaluation of 566 cases of ameloblastoma in Nigeria by the African oral pathology research consortium. Oral Cancer 3:9\u201315. https:\/\/doi.org\/10.1007\/s41548-019-00018-6","journal-title":"Oral Cancer"},{"key":"1893_CR7","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1007\/s40615-024-01993-3","volume":"12","author":"S Vila","year":"2025","unstructured":"Vila S, Oster RA, James S, Morlandt AB, Powell KK, Amm HM (2025) A retrospective analysis of 129 ameloblastoma cases: clinical and demographical trends from a single institution. J Racial Ethn Health Disparities 12:1612\u20131620. https:\/\/doi.org\/10.1007\/s40615-024-01993-3","journal-title":"J Racial Ethn Health Disparities"},{"key":"1893_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ijom.2019.11.004","volume":"49","author":"BR Chrcanovic","year":"2020","unstructured":"Chrcanovic BR, Gomes CC, Gomez RS (2020) Desmoplastic ameloblastoma: a systematic review of the cases reported in the literature. Int J Oral Maxillofac Surg 49:709\u2013716. https:\/\/doi.org\/10.1016\/j.ijom.2019.11.004","journal-title":"Int J Oral Maxillofac Surg"},{"key":"1893_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/odi.13770","volume":"28","author":"A Zlotogorski-Hurvitz","year":"2022","unstructured":"Zlotogorski-Hurvitz A, Soluk Tekke\u015fin M, Passador-Santos F, Martins Montalli VA, Salo T, Mauramo M, Kats L, Buchner A, Vered M (2022) Conceptual changes in ameloblastoma: suggested re-classification of a veteran tumor. Oral Dis 28:703\u2013710. https:\/\/doi.org\/10.1111\/odi.13770","journal-title":"Oral Dis"},{"key":"1893_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12105-024-01686-7","volume":"18","author":"P Inthong","year":"2024","unstructured":"Inthong P, Upalananda W, Saepoo J (2024) Factors associated with recurrence of ameloblastoma: a scoping review. Head Neck Pathol 18:82. https:\/\/doi.org\/10.1007\/s12105-024-01686-7","journal-title":"Head Neck Pathol"},{"key":"1893_CR11","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.7150\/ijms.61500","volume":"18","author":"L Bi","year":"2021","unstructured":"Bi L, Wei D, Hong D, Wang J, Qian K, Wang H, Zhu H (2021) A retrospective study of 158 cases on the risk factors for recurrence in ameloblastoma. Int J Med Sci 18:3326\u20133332. https:\/\/doi.org\/10.7150\/ijms.61500","journal-title":"Int J Med Sci"},{"key":"1893_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s12105-016-0734-5","volume":"10","author":"T Milman","year":"2016","unstructured":"Milman T, Ying GS, Pan W, LiVolsi V (2016) Ameloblastoma: 25 year experience at a single institution. Head Neck Pathol 10:513\u2013520. https:\/\/doi.org\/10.1007\/s12105-016-0734-5","journal-title":"Head Neck Pathol"},{"key":"1893_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jtumed.2021.09.007","volume":"17","author":"P Bwambale","year":"2022","unstructured":"Bwambale P, Yahaya JJ, Owor G, Wabinga H (2022) Histopathological patterns and biological characteristics of ameloblastoma: a retrospective cross-sectional study. J Taibah Univ Med Sci 17:96\u2013104. https:\/\/doi.org\/10.1016\/j.jtumed.2021.09.007","journal-title":"J Taibah Univ Med Sci"},{"key":"1893_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ijom.2009.11.022","volume":"39","author":"ER Fregnani","year":"2010","unstructured":"Fregnani ER, da Cruz Perez DE, de Almeida OP, Kowalski LP, Soares FA, de Abreu Alves F (2010) Clinicopathological study and treatment outcomes of 121 cases of ameloblastomas. Int J Oral Maxillofac Surg 39:145\u2013149. https:\/\/doi.org\/10.1016\/j.ijom.2009.11.022","journal-title":"Int J Oral Maxillofac Surg"},{"key":"1893_CR15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/jop.13228","volume":"50","author":"YC Goh","year":"2021","unstructured":"Goh YC, Siriwardena B, Tilakaratne WM (2021) Association of clinicopathological factors and treatment modalities in the recurrence of ameloblastoma: analysis of 624 cases. J Oral Pathol Med 50:927\u2013936. https:\/\/doi.org\/10.1111\/jop.13228","journal-title":"J Oral Pathol Med"},{"issue":"6","key":"1893_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/s0901-5027(98)80037-4","volume":"27","author":"AA Olaitan","year":"1998","unstructured":"Olaitan AA, Arole G, Adekeye EO (1998) Recurrent ameloblastoma of the jaws. A follow-up study. Int J Oral Maxillofac Surg 27, 456\u2009\u2013\u200960","journal-title":"Int J Oral Maxillofac Surg"},{"key":"1893_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/0964-1955(94)00037-5","volume":"31b","author":"PA Reichart","year":"1995","unstructured":"Reichart PA, Philipsen HP, Sonner S (1995) Ameloblastoma: biological profile of 3677 cases. Eur J Cancer B Oral Oncol 31b:86\u201399. https:\/\/doi.org\/10.1016\/0964-1955(94)00037-5","journal-title":"Eur J Cancer B Oral Oncol"},{"key":"1893_CR18","doi-asserted-by":"publisher","first-page":"217448","DOI":"10.1016\/j.canlet.2025.217448","volume":"612","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Xiong G, Wang C, Cao W (2025) From pathogenesis to precision medicine: transformative advances in research and treatment of ameloblastoma. Cancer Lett 612:217448. https:\/\/doi.org\/10.1016\/j.canlet.2025.217448","journal-title":"Cancer Lett"},{"key":"1893_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.2986","volume":"46","author":"RT Sweeney","year":"2014","unstructured":"Sweeney RT, McClary AC, Myers BR, Biscocho J, Neahring L, Kwei KA, Qu K, Gong X, Ng T, Jones CD, Varma S, Odegaard JI, Sugiyama T, Koyota S, Rubin BP, Troxell ML, Pelham RJ, Zehnder JL, Beachy PA, Pollack JR, West RB (2014) Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet 46:722\u2013725. https:\/\/doi.org\/10.1038\/ng.2986","journal-title":"Nat Genet"},{"key":"1893_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4137\/bic.S29329","volume":"7","author":"NA Brown","year":"2015","unstructured":"Brown NA, Betz BL (2015) Ameloblastoma: a review of recent molecular pathogenetic discoveries. Biomark Cancer 7:19\u201324. https:\/\/doi.org\/10.4137\/bic.S29329","journal-title":"Biomark Cancer"},{"key":"1893_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/path.4317","volume":"232","author":"KJ Kurppa","year":"2014","unstructured":"Kurppa KJ, Cat\u00f3n J, Morgan PR, Ristim\u00e4ki A, Ruhin B, Kellokoski J, Elenius K, Heikinheimo K (2014) High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 232:492\u2013498. https:\/\/doi.org\/10.1002\/path.4317","journal-title":"J Pathol"},{"key":"1893_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00428-018-2305-5","volume":"472","author":"SE G\u00fcltekin","year":"2018","unstructured":"G\u00fcltekin SE, Aziz R, Heydt C, Seng\u00fcven B, Z\u00f6ller J, Safi AF, Kreppel M, Buettner R (2018) The landscape of genetic alterations in ameloblastomas relates to clinical features. Virchows Arch 472:807\u2013814. https:\/\/doi.org\/10.1007\/s00428-018-2305-5","journal-title":"Virchows Arch"}],"updated-by":[{"DOI":"10.1007\/s12105-026-01914-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000}}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-026-01893-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-026-01893-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-026-01893-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:46:00Z","timestamp":1781635560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-026-01893-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1893"],"URL":"https:\/\/doi.org\/10.1007\/s12105-026-01893-4","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the caption for Figure 3B, \u201cRed and gray arrows\u201d is needed to be changed to \u201cGray and red arrows.\u201d","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12105-026-01914-2","URL":"https:\/\/doi.org\/10.1007\/s12105-026-01914-2","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.T., N.H., T.B., A.P., E.Z., H.S., M.D., and A.B. declare that they have no conflicts of interest. J.H. serves as a paid consultant for RiboX Therapeutics, Princeton, NJ (circular RNA research firm).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the University of Iowa Institutional Review Board (IRB #202504626) and conducted in accordance with federal guidelines and the principles of the World Medical Association Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"For this type of study consent for publication is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This study has obtained IRB approval from the University of Iowa Institutional Review Board (IRB #202504626) and the need for informed consent was waived.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}],"article-number":"25"}}